- Drug Class
- Folate Antagonist
- Mechanism of Action (MOA)
- Sequential folate-synthesis blockade (sulfamethoxazole → dihydropteroate synthase; trimethoprim → dihydrofolate reductase).
- Clinical Notes
- UTIs, PCP prophylaxis/treatment; community MRSA use is off-label; hyperkalemia; avoid in sulfa allergy & pregnancy.
Sources
Reviewed September 2026- FDA label — FDA / DailyMed
Checked against the guideline or standard reference the exam keys to. If it has moved, use Report an error below.
All pharmacology